All feline diagnoses

Your cat was diagnosed with Mediastinal Lymphoma. Often associated with FeLV infection, particularly in young cats. Siamese cats may develop FeLV-negative form. Presents with pleural effusion and respiratory distress. Compare 9 treatment options for cats including COP Protocol, CHOP Protocol, L-Asparaginase Induction — with survival times, costs, and what to expect during treatment.

🐈

Mediastinal Lymphoma

mediastinal

BreedsSiamese (FeLV-negative form)
feline

Round Cell

About This Cancer

Mediastinal lymphoma arises from the thymus gland or lymph nodes in the mediastinum — the central compartment of the chest between the lungs. It is strongly associated with feline leukaemia virus (FeLV) infection, particularly in young cats. The tumour typically consists of malignant T-lymphocytes and grows as a large mass in the chest cavity, often causing fluid to accumulate around the lungs (pleural effusion). Affected cats present with difficulty breathing, sometimes quite suddenly and severely. Siamese cats can develop a FeLV-negative form. Chemotherapy can produce meaningful remission in some cases, and FeLV-negative cats generally have a better response than FeLV-positive cats. The condition is primarily seen in younger cats (typically between 2 and 5 years of age), in contrast to most other feline lymphoma types which tend to affect older cats.

WHO Modified Staging for Feline Lymphoma

Standard feline lymphoma staging. Mediastinal lymphoma typically presents as Stage I (single extranodal site) or higher if disseminated.

Stage ISingle tumour (extranodal) or single anatomic area (nodal)
Stage IITwo or more tumours on same side of diaphragm
Stage IIITumours on both sides of diaphragm
Stage IVLiver and/or spleen involvement
Stage VBone marrow or blood involvement
Prognostic Factors(5)
FeLV statusFeLV-positive cats have decreased remission times — MST ~2-3 months vs FeLV-negative MST ~9 months(Fabrizio et al., 2014)
Achievement of complete responseCR: MST 980 days. PR: MST 42 days (dramatic difference).(Fabrizio et al., 2014)
AgeCats <4 years: MST 373 days. Cats >=4 years: MST 212 days.(Fabrizio et al., 2014)
FeLV-positive management considerationsFeLV-positive cats may still benefit from chemotherapy but have shorter remission times (MST ~2-3 months). Full-protocol chemotherapy is generally recommended despite FeLV status — immunosuppression from chemotherapy is temporary, while untreated lymphoma is uniformly fatal. Monitor viral load if possible. Manage secondary infections aggressively. Avoid prolonged immunosuppressive corticosteroid monotherapy in FeLV-positive cats as it may accelerate viral disease progression without adequate tumour control.(Fabrizio et al., 2014)
FeLV management in FeLV-positive catsFeLV-positive cats can receive full-protocol chemotherapy but have shorter remission times (MST ~2-3 months vs ~9 months FeLV-negative). No evidence that concurrent antiviral therapy improves lymphoma outcomes. Monitor viral load where available. Immunosuppression from chemotherapy may transiently increase viraemia. Prognosis remains guarded regardless of treatment intensity.(Fabrizio et al., 2014)
Minimum Workup(9 steps)
1CRITICAL WARNING: Avoid administering prednisolone/prednisone BEFORE obtaining biopsy/cytology — corticosteroids can induce multi-drug resistance (MDR) and cause rapid tumour lysis, making subsequent histopathological diagnosis difficult or impossible. Complete diagnostic workup BEFORE starting any corticosteroid therapy.
2CBC, comprehensive chemistry panel
3FeLV/FIV testing (critical — impacts prognosis)
4Thoracic radiographs (mediastinal mass, pleural effusion)
5Pleural fluid cytology (often diagnostic)
6Thoracic ultrasound
7Fine needle aspirate of mass if accessible
8Abdominal ultrasound (staging)
9Flow cytometry or PARR if phenotyping needed

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
COP Protocol
~16 mo (1–32)
CHOP Protocol
See notes
L-Asparaginase Induction
See notes
Prednisolone Alone
~2 mo (1–3)
Radiation Therapy (Residual Disease)
See notes
Rescue/Relapse Guidance
See notes
Lomustine (CCNU) Rescue
See notes
Single-Agent Doxorubicin Rescue
See notes
Protocol Switch (COP↔CHOP)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.